Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Dec;77(16):1592-1600.
doi: 10.1002/pros.23436. Epub 2017 Oct 10.

Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH

Zachary S Zumsteg  1   2 , Zinan Chen  3 , Lauren E Howard  3   4 , Christopher L Amling  5 , William J Aronson  6   7 , Matthew R Cooperberg  8 , Christopher J Kane  9 , Martha K Terris  10   11 , Daniel E Spratt  12 , Howard M Sandler  1   2 , Stephen J Freedland  1   4   13
Affiliations
Multicenter Study

Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH

Zachary S Zumsteg et al. Prostate. 2017 Dec.

Abstract

Introduction: Prostate cancer is a heterogeneous disease, and risk stratification systems have been proposed to guide treatment decisions. However, significant heterogeneity remains for those with unfavorable-risk disease.

Methods: This study included 3335 patients undergoing radical prostatectomy without adjuvant radiotherapy in the SEARCH database. High-risk patients were dichotomized into standard and very high-risk (VHR) groups based on primary Gleason pattern, percentage of positive biopsy cores (PPBC), number of NCCN high-risk factors, and stage T3b-T4 disease. Similarly, intermediate-risk prostate cancer was separated into favorable and unfavorable groups based on primary Gleason pattern, PPBC, and number of NCCN intermediate-risk factors.

Results: Median follow-up was 78 months. Patients with VHR prostate cancer had significantly worse PSA relapse-free survival (PSA-RFS, P < 0.001), distant metastasis (DM, P = 0.004), and prostate cancer-specific mortality (PCSM, P = 0.015) in comparison to standard high-risk (SHR) patients in multivariable analyses. By contrast, there was no significant difference in PSA-RFS, DM, or PCSM between SHR and unfavorable intermediate-risk (UIR) patients. Therefore, we propose a novel risk stratification system: Group 1 (low-risk), Group 2 (favorable intermediate-risk), Group 3 (UIR and SHR), and Group 4 (VHR). The c-index of this new grouping was 0.683 for PSA-RFS and 0.800 for metastases, compared to NCCN-risk groups which yield 0.666 for PSA-RFS and 0.764 for metastases.

Conclusions: Patients classified as VHR have markedly increased rates of PSA relapse, DM, and PCSM in comparison to SHR patients, whereas UIR and SHR patients have similar prognosis. Novel therapeutic strategies are needed for patients with VHR, likely involving multimodality therapy.

Keywords: prostate cancer; risk stratification; unfavorable intermediate risk; very high-risk prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest relevant to this manuscript to report

Figures

Figure 1
Figure 1
Cumulative incidence of A) PSA recurrence (PSA-RFS), B) distant metastasis (DM), C) prostate cancer-specific mortality (PCSM), and D) all cause-mortality (ACM) for low risk, favorable intermediate risk (FIR), unfavorable intermediate risk (UIR), standard high risk (SHR) and very high risk (VHR) cohorts.
Figure 1
Figure 1
Cumulative incidence of A) PSA recurrence (PSA-RFS), B) distant metastasis (DM), C) prostate cancer-specific mortality (PCSM), and D) all cause-mortality (ACM) for low risk, favorable intermediate risk (FIR), unfavorable intermediate risk (UIR), standard high risk (SHR) and very high risk (VHR) cohorts.
Figure 2
Figure 2
Cumulative incidence of A) PSA recurrence (PSA-RFS), B) distant metastasis (DM), C) prostate cancer-specific mortality (PCSM), and D) all cause-mortality (ACM) for proposed 4-tier risk stratification system.
Figure 2
Figure 2
Cumulative incidence of A) PSA recurrence (PSA-RFS), B) distant metastasis (DM), C) prostate cancer-specific mortality (PCSM), and D) all cause-mortality (ACM) for proposed 4-tier risk stratification system.
See this image and copyright information in PMC

References

    1. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13. - PMC - PubMed
    1. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272–7. - PubMed
    1. Sundi D, Wang VM, Pierorazio PM, et al. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis. 2014;17:57–63. - PMC - PubMed
    1. Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20:2846–50. - PMC - PubMed
    1. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12:686–718. - PubMed

Publication types